Matthew During - One of the world’s foremost researchers in neuroscience and genetics
A graduate of the University of Auckland, Dr. Matthew During holds a Bachelor of Science in Human Biology and a Doctor of Medicine. After earning his medical degree, he continued his education with a postdoctoral fellowship in neuroscience at Massachusetts Institute of Technology, where he worked with R.J. Wurtman, M.D. He simultaneously completed a residency in neurology through Harvard Medical School at Massachusetts General Hospital and secured a Fogarty Fellowship in molecular pharmacology and psychiatry at the Yale University School of Medicine. Subsequently, Dr. During completed a clinical fellowship in neurosurgery at Yale and later returned to the University of Auckland, where he earned a Doctor of Science in Neuroscience & Genetics.
At present, he teaches at The Ohio State University in Columbus as a Professor of Molecular Virology, Immunology, Medical Genetics, Neuroscience, and Neurosurgery. In addition, he functions as a Professor of Molecular Medicine at the University of Auckland and as a Visiting Professor of Translational Neuroscience at the University of Oxford. Dr. Matthew During has taught at the Yale University School of Medicine, Jefferson Medical College, and the Weill Cornell Medical College.
This year, he founded Obgenex, Inc., a biotechnology firm that focuses on obesity and metabolic disorders. He serves as the Chief Scientific Officer for the firm. He previously founded Neurologix, Inc., a company commmercializing genetic therapies for Parkinson's disease. In 2010, he established Gene Technology Solutions, also known as GTS, Inc., a firm that researches adeno-associated virus (AAV) technology, through which scientists can deliver genes to human cells for therapeutic effects.